Compare NAC & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NAC | DFTX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | NAC | DFTX |
|---|---|---|
| Price | $11.65 | $18.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $40.25 |
| AVG Volume (30 Days) | 614.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.35 | $14.62 |
| 52 Week High | $12.25 | $19.67 |
| Indicator | NAC | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 56.78 |
| Support Level | $11.22 | $16.26 |
| Resistance Level | $11.64 | $19.55 |
| Average True Range (ATR) | 0.11 | 1.01 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 41.67 | 69.69 |
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).